Clough Capital Partners
VC Fund
Boston, United States
Clough Capital Partners is a VC fund in Boston focused on Biotechnology and Therapeutics. Clough Capital Partners, L.P. is a Boston-based investment management firm
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Clough Capital Partners invests in
Stages Clough Capital Partners invests in
Countries Clough Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chuck Clough
|
|||
Investment Focus
Industry
- Biotechnology 8 (100%)
- Therapeutics 4 (50%)
- Medical 3 (38%)
- Health Care 3 (38%)
- Pharmaceutical 3 (38%)
Stage
- Series B 3 (38%)
- Series C 2 (25%)
- Series E 2 (25%)
- Series D 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chuck Clough
Chairman, CEO & Portfolio Manager
|
Chairman, CEO & Portfolio Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Amunix
|
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness theimmune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies.Amunix was founded in 2006 and is headquartered in Mountain View, California. | $117M / Series B / Mar 04, 2021 | |
Checkmate Pharmaceuticals
|
Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapiesdesigned to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers.Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts. | $85M / Series C / Jun 10, 2020 | |
Amphivena Therapeutics
|
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, andenhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing.It was founded in 2012 and is headquartered in South San Francisco, California. | $62M / Series C / Sep 24, 2019 | |
Apellis Pharmaceuticals
|
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, andcompassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. | Series E / Aug 10, 2017 | |
Sienna Biopharmaceuticals
|
Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine. | $40M / Series B / Apr 24, 2017 | |
CRISPR Therapeutics
|
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from theirscientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK. | $38M / Series B / Jun 24, 2016 | |
Elcelyx Therapeutics
|
Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMetfor Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market.Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.Elcelyx is headquartered in San Diego, California. | $40M / Series E / Oct 01, 2015 | |
Aduro BioTech
|
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. It was founded in 2000 and headquartered in Berkeley, California. | $51.4M / Series D / Jan 05, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Clough Capital Partners invest in?
Clough Capital Partners invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Clough Capital Partners?
Public channels for Clough Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Clough Capital Partners?
The team at Clough Capital Partners includes Chuck Clough (Chairman, CEO & Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
